Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study

BACKGROUND: Pancreatic cancer is a deadly disease with a low five years survival rate, and chemotherapy remains the standard treatment for advanced cases. However, the efficacy of chemotherapy alone is limited, and there is a need for new treatment options. Recently, immune checkpoint inhibitors (IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhitao, He, Yahui, Ding, Chenchen, Chen, Jun, Gu, Yangjun, Xiao, Min, Li, Qiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642393/
https://www.ncbi.nlm.nih.gov/pubmed/37965584
http://dx.doi.org/10.2147/OTT.S427942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642393/
https://www.ncbi.nlm.nih.gov/pubmed/37965584
http://dx.doi.org/10.2147/OTT.S427942

Ejemplares similares